ABSTRACT

Neuroleptic malignant syndrome (NMS) is a rare syndrome which can be fatal and characterized by hyperthermia, muscular rigidity, changes in consciousness, autonomic dysfunction, increased serum creatinine kinase and leukocytosis. We present a case with metastatic gastric cancer developed neuroleptic malignant syndrome after metoclopropamide treatment. Metoclopropamide-associated neuroleptic malignant syndrome is a rare life-threatening condition. It occurs due to blockade of dopamin receptors by metoclopropamid in brain and high cholinergic stimulation